This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Explorna Therapeutics Sp. Z O.O., Uniwersytet Warszawski. Active years: 2026.
Company Filing History:
1 out of 2 
1 out of 3 Years Active: 2026
Title: Marcin Warminski: Innovator in mRNA Technology
Introduction
Marcin Warminski is a notable inventor based in Warszawa, Poland. He has made significant contributions to the field of nucleotides and mRNA technology. His work focuses on developing innovative solutions that may have therapeutic applications.
Latest Patents
Marcin Warminski holds a patent titled "5'-Phosphorothiolate mRNA 5'-End (cap) Analogs, mRNA Comprising The Same, Method Of Obtaining And Uses Thereof." This invention relates to nucleotides and analogs of mRNA 5'-end (cap) that contain a sulfur atom at the position 5' of the 7-methylguanosine nucleoside. The disclosed compounds are recognized by the DcpS enzyme, which may find therapeutic use as inhibitors in treating spinal muscular atrophy (SMA). The invention also includes mRNAs modified at the 5' end with these analogs, which exhibit increased stability and translational activity in cellular conditions.
Career Highlights
Marcin Warminski is affiliated with the University of Warsaw, where he continues to advance his research in mRNA technology. His work has the potential to impact therapeutic strategies for various diseases, particularly those related to genetic disorders.
Collaborations
Some of his notable coworkers include Jacek Jemielity and Kaja Fac-Dabrowska, who contribute to the research and development of innovative solutions in the field.
Conclusion
Marcin Warminski is a pioneering inventor whose work in mRNA technology holds promise for future therapeutic applications. His contributions to the field are noteworthy and reflect his commitment to advancing scientific knowledge.